Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1988 3
1989 5
1990 3
1992 1
1993 4
1994 4
1995 3
1996 2
1997 2
1998 4
1999 1
2000 2
2001 3
2002 3
2003 3
2004 6
2005 6
2006 4
2007 17
2008 26
2009 18
2010 20
2011 14
2012 26
2013 15
2014 15
2015 19
2016 20
2017 18
2018 16
2019 14
2020 15
2021 20
2022 15
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

308 results

Results by year

Filters applied: . Clear all
Page 1
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, Muñoz M, Bermejo B, Margeli M, Anton A, Kahan Z, Csöszi T, Casas MI, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, Calvo L, de la Haba-Rodriguez J, Ramos M, Alvarez I, Garcia-Palomo A, Huang Bartlett C, Koehler M, Caballero R, Corsaro M, Huang X, Garcia-Sáenz JA, Chacón JI, Swift C, Thallinger C, Gil-Gil M. Martin M, et al. Among authors: calvo l. Ann Oncol. 2021 Apr;32(4):488-499. doi: 10.1016/j.annonc.2020.12.013. Epub 2020 Dec 29. Ann Oncol. 2021. PMID: 33385521 Free article. Clinical Trial.
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano Á, García-Sáenz JA, Torres R, de la Haba J, García-Martínez E, Gómez HL, Llombart A, Bofill JS, Baena-Cañada JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Fernández I, Rodríguez-Lescure Á, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Martín M; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group). Lluch A, et al. Among authors: calvo l. J Clin Oncol. 2020 Jan 20;38(3):203-213. doi: 10.1200/JCO.19.00904. Epub 2019 Dec 5. J Clin Oncol. 2020. PMID: 31804894 Free PMC article. Clinical Trial.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A; PHERGain steering committee and trial investigators. Pérez-García JM, et al. Among authors: calvo l. Lancet Oncol. 2021 Jun;22(6):858-871. doi: 10.1016/S1470-2045(21)00122-4. Epub 2021 May 18. Lancet Oncol. 2021. PMID: 34019819 Clinical Trial.
Breast cancer management in the elderly.
Luque M, Arranz F, Cueva JF, de Juan A, García-Teijido P, Calvo L, Peláez I, García-Palomo A, García-Mata J, Antolín S, García-Estévez L, Fernández Y. Luque M, et al. Among authors: calvo l. Clin Transl Oncol. 2014 Apr;16(4):351-61. doi: 10.1007/s12094-013-1113-2. Epub 2013 Oct 2. Clin Transl Oncol. 2014. PMID: 24085574 Review.
Mitral annular disjunction: Beyond mitral valve prolapse.
Faria B, Ribeiro S, Calvo L, Oliveira M, von Hafe P, Bettencourt N, Sanfins V, Lourenço A. Faria B, et al. Among authors: calvo l. Rev Port Cardiol. 2023 Oct;42(10):873-878. doi: 10.1016/j.repc.2019.09.024. Epub 2023 May 6. Rev Port Cardiol. 2023. PMID: 37156414 Free article. Review. English, Portuguese.
Circulating microRNAs: molecular microsensors in gastrointestinal cancer.
Blanco-Calvo M, Calvo L, Figueroa A, Haz-Conde M, Antón-Aparicio L, Valladares-Ayerbes M. Blanco-Calvo M, et al. Among authors: calvo l. Sensors (Basel). 2012;12(7):9349-62. doi: 10.3390/s120709349. Epub 2012 Jul 9. Sensors (Basel). 2012. PMID: 23012546 Free PMC article. Review.
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M. González-Martín A, et al. Among authors: calvo l. Curr Cancer Drug Targets. 2016;16(5):415-28. doi: 10.2174/1568009615666150817121731. Curr Cancer Drug Targets. 2016. PMID: 26278712 Review.
Clinical implications of epithelial cell plasticity in cancer progression.
Aparicio LA, Blanco M, Castosa R, Concha Á, Valladares M, Calvo L, Figueroa A. Aparicio LA, et al. Among authors: calvo l. Cancer Lett. 2015 Sep 28;366(1):1-10. doi: 10.1016/j.canlet.2015.06.007. Epub 2015 Jun 19. Cancer Lett. 2015. PMID: 26099173 Free article. Review.
Update in pharmacological management of coronary no-reflow phenomenon.
Salinas P, Jimenez-Valero S, Moreno R, Sanchez-Recalde A, Galeote G, Calvo L, Ruiz-Garcia J, Carrizo S, Trucco G, Lopez-Sendon J. Salinas P, et al. Among authors: calvo l. Cardiovasc Hematol Agents Med Chem. 2012 Sep;10(3):256-64. doi: 10.2174/187152512802651024. Cardiovasc Hematol Agents Med Chem. 2012. PMID: 22827250 Review.
308 results